Pain Therapeutics 2005 Explains Just What the Cox-II Crisis Means for the Future of Pain Management

Research and Markets has announced the addition of Pain Therapeutics 2005:Market Dynamics and Outlook to their offering.

Dublin (PRWEB) March 2, 2006 -- Research and Markets (http://www.researchandmarkets.com/reports/c33714) has announced the addition of Pain Therapeutics 2005:Market Dynamics and Outlook to their offering.

Pain Therapeutics 2005: Market Dynamics and Outlook provides detailed analysis and information concerning the global market for pain therapeutics, R&D pipelines and company involvement in this field.

About one and a half billion people suffer from moderate to severe chronic pain worldwide and approximately 50 million Americans suffer with pain. The value of the pharmaceutical market for pain relief reflects this seeming worldwide epidemic of pain, with the overall value reaching nearly $23 billion in 2004.

In this new report, key pain management therapeutics such as Cox-II inhibitors, opioids, triptans, anticonvulsants and traditional NSAIDs are discussed in terms of their past, present and future value and the role they are playing in the effective management of pain.

The dynamics of this market have been altered greatly over the past year. The troubles surrounding the multi-billion dollar Cox-II class has created a void in the marketplace. Pain Therapeutics 2005 explains just what the Cox-II crisis means for the future of pain management and what kinds of opportunities their failure may present for other classes of pain management medications.

Pain Therapeutics 2005 also analyzes the markets and provides forecasts for:

- the fast-growing anticonvulsant class
- migraine therapies
- traditional NSAIDs
- and opioids.

Company Profiles:

Abbott Laboratories
AlgoRx Pharmaceuticals
Altea Therapeutics
Ardent Pharmaceuticals
AstraZeneca
Cephalon
Elan Pharmaceuticals
Endo Pharmacuticals
EpiCept
GlaxoSmithKline
Indevus Pharmaceuticals
Innovative Drug Delivery Systems
Johnson & Johnson
Metaphore Pharmaceuticals
Nastech Pharmaceutical
NeurogesX
Novartis Pharmaceuticals
Pain Therapeutics
Pfizer
Purdue
Renovis
SkyePharma

For more information visit http://www.researchandmarkets.com/reports/c33714

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

###